Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche Opens Access to Pathology Imaging Tools to Improve Patient Care

09/15/2021 | 01:00am EDT

Roche announced the introduction of the Roche Digital Pathology Open Environment that allows software developers to easily integrate their image analysis tools for tumour tissue with Roche’s uPath enterprise software, an application for pathologist workflow. This open environment allows for the secure exchange and flow of data so that pathologists can access advanced algorithms from third parties alongside Roche’s menu of artificial intelligence-based image analysis tools. This enables software developers globally to distribute their digital products through Roche’s uPath software, offering a broader set of diagnostic tools for pathologists and ultimately the potential for better and faster answers for patients. As artificial intelligence tools proposed for clinical use continue to develop, industry and research partners may leverage Roche’s Open Environment. This access expands the ability for pathologists to more easily read images generated from the VENTANA DP 200 slide scanner, which is needed for image analysis algorithm development. This also allows for partnerships between researchers and developers, which can result in greater access to innovative imaging tools for laboratories and healthcare providers for both research and clinical use.


© S&P Capital IQ 2021
All news about ROCHE HOLDING AG
05:28aROCHE : family shareholders will maintain stability - vice chairman
RE
10/15ROCHE : FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With E..
BU
10/15ROCHE : US FDA approves Roche's Tecentriq as adjuvant treatment for certain people with ea..
AQ
10/15PRESS RELEASE : US FDA approves Roche's Tecentriq -2-
DJ
10/15PRESS RELEASE : US FDA approves Roche's Tecentriq as adjuvant treatment for certain people..
DJ
10/15GENENTECH : FDA Approves Tecentriq as Adjuvant Treatment for Certain Lung Cancer Patients
DJ
10/15ROCHE : Joins PathAI to Develop AI-Based Image Analysis Workflow for Pathologists
MT
10/15ROCHE : announces PathAI collaboration for artificial intelligence-based digital pathology..
AQ
10/15PRESS RELEASE : Roche announces PathAI collaboration for artificial intelligence-based dig..
DJ
10/14ROCHE : U.S. FDA advisers to review Merck's oral COVID-19 drug next month
RE
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 61 787 M 66 909 M 66 909 M
Net income 2021 14 572 M 15 780 M 15 780 M
Net cash 2021 4 469 M 4 840 M 4 840 M
P/E ratio 2021 20,9x
Yield 2021 2,60%
Capitalization 313 B 339 B 339 B
EV / Sales 2021 5,00x
EV / Sales 2022 4,86x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 360,25 CHF
Average target price 382,53 CHF
Spread / Average Target 6,19%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG16.59%339 442
JOHNSON & JOHNSON2.49%424 619
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
ELI LILLY AND COMPANY40.89%215 657
MERCK & CO., INC.-4.24%198 283